Firefly's Milestones Fail to Halt 70% Decline as Sector Headwinds Compound Execution Risk

What happened

Firefly Aerospace delivered several headline milestones—a successful Moon landing, a Pentagon contract, and a Lockheed Martin partnership—but its stock has fallen roughly 70% from recent highs, a decline driven more by sector-wide de-rating of space and defense names than company-specific news. The DeepValue master report had already flagged the stock as a WAIT at $28.90, citing persistent free cash flow losses (-$78.9 million in Q1 2026), a $344.8 million chunk of unscheduled backlog, and the need for dated launch windows and Alpha Flight 8 success to justify valuation. With the stock now likely trading below the report’s attractive entry of $24, the market is pricing in a higher probability of delays or continued cash burn, even as the company holds $551.6 million in cash and only $26.8 million in debt. The broader space and defense sector headwinds mentioned in the article compound Firefly’s execution-dependent story, as investors reappraise high-multiple, pre-profit space companies amid rising rates or risk aversion. Consequently, the balance of evidence shifts from a balanced WAIT toward a more cautious stance until Firefly provides concrete evidence of repeatable missions and improving cash flow.

Implication

Given the stock's 70% decline, it may be approaching value territory, but momentum and sector sentiment are negative, so average down cautiously. Monitor liquidity covenant compliance, mission schedule, and sector stabilization. Only consider adding if stock stabilizes near $15-17 and the company shows dated launch windows and reduced cash burn. Otherwise, avoid chasing the falling knife.

Thesis delta

The thesis weakens: the stock's 70% drop despite positive milestones suggests the market is discounting execution and sector risk more heavily than fundamentals. While the balance sheet remains decent, the absence of near-term catalysts and high cash burn lowers the probability of near-term re-rating. Thus, downgrade from WAIT to a more defensive posture, wait for evidence of schedule adherence and FCF improvement before reconsidering.